Claudin-2 inhibits renal clear cell carcinoma progression by inhibiting YAP-activation
Open Access
- 23 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1), 1-16
- https://doi.org/10.1186/s13046-021-01870-5
Abstract
Claudin-2 expression is upregulated in multiple cancers and promotes cancer malignancy. Remarkably, the regulation of claudin-2 expression in kidney cell lines contrasts its reported regulation in other organs. However, claudin-2 role in renal clear cell carcinoma (RCC) remains unknown despite its predominant expression in the proximal tubular epithelium (PTE), the site of RCC origin. Publicly available and independent patient databases were examined for claudin-2 association with RCC. The novel protein function was validated in vitro and in vivo by gain or loss of function assays. Mechanistic results were concluded by Mass spectroscopy, immunoprecipitation and mutational studies, and functional evaluations. We show that the significant decrease in claudin-2 expression characterized PTE cells and Ex-vivo cultured mouse kidney subjected to dedifferentiation. Inhibition of claudin-2 was enough to induce mesenchymal plasticity and invasive mobility in these models. Further, a progressive loss of claudin-2 expression associated with the RCC progression and poor patient survival. Overexpression of claudin-2 in RCC-derived cancer cells inhibited tumorigenic abilities and xenograft tumor growth. These data supported a novel tumor-suppressive role of claudin-2 in RCC. Mechanistic insights further revealed that claudin-2 associates with YAP-protein and modulates its phosphorylation (S127) and nuclear expression. The tumor suppressive effects of claudin-2 expression were lost upon deletion of its PDZ-binding motif emphasizing the critical role of the PDZ-domain in claudin-2 interaction with YAP in regulating RCC malignancy. Our results demonstrate a novel kidney specific tumor suppressive role for claudin-2 protein and further demonstrate that claudin-2 co-operates with the YAP signaling in regulating the RCC malignancy.Keywords
Funding Information
- National Institutes of Health (BX002761)
- U.S. Department of Veterans Affairs (BX002086, DK124095)
This publication has 54 references indexed in Scilit:
- Myeloid Cell-Derived Hypoxia-Inducible Factor Attenuates Inflammation in Unilateral Ureteral Obstruction-Induced Kidney InjuryThe Journal of Immunology, 2012
- Epithelial cell polarity: a major gatekeeper against cancer?Cell Death & Differentiation, 2011
- Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activationOncogene, 2011
- Claudin-2 Forms Homodimers and Is a Component of a High Molecular Weight Protein ComplexOnline Journal of Public Health Informatics, 2011
- Hippo signaling: growth control and beyondDevelopment, 2011
- Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to diseaseKidney International, 2009
- Epithelial-mesenchymal transitions: the importance of changing cell state in development and diseaseJCI Insight, 2009
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007
- Claudin-1 regulates cellular transformation and metastatic behavior in colon cancerJCI Insight, 2005
- Membrane-associated HB-EGF modulates HGF-induced cellular responses in MDCK cellsJournal of Cell Science, 2004